http://streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 17 Jun 2026 16:30:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Corbus+Pharmaceuticals+++++++++++++++/26660403.html si-local-file:///var/storage/secattach/20260617/26660403.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Corbus+Pharmaceuticals+++++++++++++++/26660403.html Wed, 17 Jun 2026 16:30:00 -0400 CRBP O.22488230 http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Corbus+Pharmaceuticals+++++++++++++++/26660403.html si-local-file:///var/storage/secattach/20260617/26660403.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Corbus+Pharmaceuticals+++++++++++++++/26660403.html Wed, 17 Jun 2026 16:30:00 -0400 CRBP O.22488230 http://www.streetinsider.com/Analyst+PT+Change/Corbus+Pharmaceuticals+%28CRBP%29+PT+Lowered+to+%2452+at+Oppenheimer/26656339.html (Updated - June 17, 2026 6:03 AM EDT) <p>Oppenheimer analyst Jeff Jones lowered the price target on Corbus Pharmaceuticals (NASDAQ: CRBP) to $52.00 (from $54.00) while maintaining a Outperform rating.</p><p>The analyst commented: "We recently hosted a lively investor dinner with CRBP management. The event reinforced our confidence in the opportunity for '701 in 2L OPSCC, with medical oncologist Dr. Aarti Bhatia of Yale providing background to support the size of the market and lack of options for these patients. Questions from the dinner focused on: size of the OPSCC market; current treatment approaches in 1L and 2L; validation of nectin-4 targeting; http://www.streetinsider.com/Analyst+PT+Change/Corbus+Pharmaceuticals+%28CRBP%29+PT+Lowered+to+%2452+at+Oppenheimer/26656339.html Wed, 17 Jun 2026 06:03:01 -0400 CRBP http://www.streetinsider.com/Analyst+Comments/Corbus+Pharmaceuticals+%28CRBP%29+PT+Lowered+to+%2452+at+Oppenheimer/26656339.html (Updated - June 17, 2026 6:03 AM EDT) <p>Oppenheimer analyst Jeff Jones lowered the price target on Corbus Pharmaceuticals (NASDAQ: CRBP) to $52.00 (from $54.00) while maintaining a Outperform rating.</p><p>The analyst commented: "We recently hosted a lively investor dinner with CRBP management. The event reinforced our confidence in the opportunity for '701 in 2L OPSCC, with medical oncologist Dr. Aarti Bhatia of Yale providing background to support the size of the market and lack of options for these patients. Questions from the dinner focused on: size of the OPSCC market; current treatment approaches in 1L and 2L; validation of nectin-4 targeting; http://www.streetinsider.com/Analyst+Comments/Corbus+Pharmaceuticals+%28CRBP%29+PT+Lowered+to+%2452+at+Oppenheimer/26656339.html Wed, 17 Jun 2026 06:03:01 -0400 CRBP http://www.streetinsider.com/Analyst+PT+Change/Corbus+Pharmaceuticals+%28CRBP%29+PT+Lowered+to+%2452+at+Oppenheimer/26656364.html <p>Oppenheimer analyst Jeff Jones lowered the price target on Corbus Pharmaceuticals (NASDAQ: CRBP) to $52.00 (from $54.00) while maintaining a Outperform rating.</p><p>The analyst comments "We recently hosted a lively investor dinner with CRBP management. The event reinforced our confidence in the opportunity for '701 in 2L OPSCC, with medical oncologist Dr. Aarti Bhatia of Yale providing background to support the size of the market and lack of options for these patients. Questions from the dinner focused on: size of the OPSCC market; current treatment approaches in 1L and 2L; validation of nectin-4 targeting; and expert view on efficacy and safety http://www.streetinsider.com/Analyst+PT+Change/Corbus+Pharmaceuticals+%28CRBP%29+PT+Lowered+to+%2452+at+Oppenheimer/26656364.html Wed, 17 Jun 2026 06:03:01 -0400 CRBP http://www.streetinsider.com/Analyst+Comments/Corbus+Pharmaceuticals+%28CRBP%29+PT+Lowered+to+%2452+at+Oppenheimer/26656364.html <p>Oppenheimer analyst Jeff Jones lowered the price target on Corbus Pharmaceuticals (NASDAQ: CRBP) to $52.00 (from $54.00) while maintaining a Outperform rating.</p><p>The analyst comments "We recently hosted a lively investor dinner with CRBP management. The event reinforced our confidence in the opportunity for '701 in 2L OPSCC, with medical oncologist Dr. Aarti Bhatia of Yale providing background to support the size of the market and lack of options for these patients. Questions from the dinner focused on: size of the OPSCC market; current treatment approaches in 1L and 2L; validation of nectin-4 targeting; and expert view on efficacy and safety http://www.streetinsider.com/Analyst+Comments/Corbus+Pharmaceuticals+%28CRBP%29+PT+Lowered+to+%2452+at+Oppenheimer/26656364.html Wed, 17 Jun 2026 06:03:01 -0400 CRBP http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Corbus+Pharmaceuticals++++For%3A+Jun+10++Filed+by%3A+Jenkins+John+Kenneth/26636162.html si-local-file:///var/storage/secattach/20260611/26636162.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Corbus+Pharmaceuticals++++For%3A+Jun+10++Filed+by%3A+Jenkins+John+Kenneth/26636162.html Thu, 11 Jun 2026 16:30:00 -0400 CRBP O.22488230 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Corbus+Pharmaceuticals++++For%3A+Jun+10++Filed+by%3A+Jenkins+John+Kenneth/26636162.html si-local-file:///var/storage/secattach/20260611/26636162.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Corbus+Pharmaceuticals++++For%3A+Jun+10++Filed+by%3A+Jenkins+John+Kenneth/26636162.html Thu, 11 Jun 2026 16:30:00 -0400 CRBP O.22488230 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Corbus+Pharmaceuticals++++For%3A+Jun+10++Filed+by%3A+Altmeyer+Anne/26636166.html si-local-file:///var/storage/secattach/20260611/26636166.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Corbus+Pharmaceuticals++++For%3A+Jun+10++Filed+by%3A+Altmeyer+Anne/26636166.html Thu, 11 Jun 2026 16:30:00 -0400 CRBP O.22488230 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Corbus+Pharmaceuticals++++For%3A+Jun+10++Filed+by%3A+Altmeyer+Anne/26636166.html si-local-file:///var/storage/secattach/20260611/26636166.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Corbus+Pharmaceuticals++++For%3A+Jun+10++Filed+by%3A+Altmeyer+Anne/26636166.html Thu, 11 Jun 2026 16:30:00 -0400 CRBP O.22488230 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Corbus+Pharmaceuticals++++For%3A+Jun+10++Filed+by%3A+Kung+Winston/26636169.html si-local-file:///var/storage/secattach/20260611/26636169.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Corbus+Pharmaceuticals++++For%3A+Jun+10++Filed+by%3A+Kung+Winston/26636169.html Thu, 11 Jun 2026 16:30:00 -0400 CRBP O.22488230 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Corbus+Pharmaceuticals++++For%3A+Jun+10++Filed+by%3A+Kung+Winston/26636169.html si-local-file:///var/storage/secattach/20260611/26636169.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Corbus+Pharmaceuticals++++For%3A+Jun+10++Filed+by%3A+Kung+Winston/26636169.html Thu, 11 Jun 2026 16:30:00 -0400 CRBP O.22488230 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Corbus+Pharmaceuticals++++For%3A+Jun+02++Filed+by%3A+Saxena+Nishant+C/26600549.html si-local-file:///var/storage/secattach/20260603/26600549.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Corbus+Pharmaceuticals++++For%3A+Jun+02++Filed+by%3A+Saxena+Nishant+C/26600549.html Wed, 03 Jun 2026 17:37:00 -0400 CRBP O.22488230 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Corbus+Pharmaceuticals++++For%3A+Jun+02++Filed+by%3A+Saxena+Nishant+C/26600549.html si-local-file:///var/storage/secattach/20260603/26600549.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Corbus+Pharmaceuticals++++For%3A+Jun+02++Filed+by%3A+Saxena+Nishant+C/26600549.html Wed, 03 Jun 2026 17:37:00 -0400 CRBP O.22488230 http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Corbus+Pharmaceuticals+++++++++++++++/26576139.html si-local-file:///var/storage/secattach/20260529/26576139.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Corbus+Pharmaceuticals+++++++++++++++/26576139.html Fri, 29 May 2026 16:51:00 -0400 CRBP O.22488230 http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Corbus+Pharmaceuticals+++++++++++++++/26576139.html si-local-file:///var/storage/secattach/20260529/26576139.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Corbus+Pharmaceuticals+++++++++++++++/26576139.html Fri, 29 May 2026 16:51:00 -0400 CRBP O.22488230 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Corbus+Pharmaceuticals++++For%3A+May+26/26546647.html si-local-file:///var/storage/secattach/20260526/26546647.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Corbus+Pharmaceuticals++++For%3A+May+26/26546647.html Tue, 26 May 2026 08:56:00 -0400 CRBP O.22488230 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Corbus+Pharmaceuticals++++For%3A+May+26/26546647.html si-local-file:///var/storage/secattach/20260526/26546647.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Corbus+Pharmaceuticals++++For%3A+May+26/26546647.html Tue, 26 May 2026 08:56:00 -0400 CRBP O.22488230 http://www.streetinsider.com/FDA/Corbus+reports+CRB-701+shows+42.9%25+response+rate+in+oropharyngeal+cancer/26545684.html <p>Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) reported updated Phase 1/2 clinical trial data for its antibody drug conjugate CRB-701, showing a confirmed objective response rate of 42.9% in second-line oropharyngeal squamous cell carcinoma at the 3.6 mg/kg dose.</p> <p>The data, based on an April 1, 2026 data cut from a multi-center study conducted in the U.S. and Europe, included 317 patients across all tumor types and doses. In oropharyngeal cancer patients treated at 3.6 mg/kg, the median duration of response was 6.3 months and progression-free survival was 5.6 months.</p> <p>For cervical cancer patients at the same dose, CRB-701 demonstrated a confirmed objective http://www.streetinsider.com/FDA/Corbus+reports+CRB-701+shows+42.9%25+response+rate+in+oropharyngeal+cancer/26545684.html Tue, 26 May 2026 07:00:54 -0400 A.06822034 A.08498496 A.20922990 A.50216777 CRBP O.00048977 O.01199884 O.20026344 O.22488230 O.54516537 http://www.streetinsider.com/FDA/Corbus+reports+CRB-701+shows+42.9%25+response+rate+in+oropharyngeal+cancer/26545684.html <p>Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) reported updated Phase 1/2 clinical trial data for its antibody drug conjugate CRB-701, showing a confirmed objective response rate of 42.9% in second-line oropharyngeal squamous cell carcinoma at the 3.6 mg/kg dose.</p> <p>The data, based on an April 1, 2026 data cut from a multi-center study conducted in the U.S. and Europe, included 317 patients across all tumor types and doses. In oropharyngeal cancer patients treated at 3.6 mg/kg, the median duration of response was 6.3 months and progression-free survival was 5.6 months.</p> <p>For cervical cancer patients at the same dose, CRB-701 demonstrated a confirmed objective http://www.streetinsider.com/FDA/Corbus+reports+CRB-701+shows+42.9%25+response+rate+in+oropharyngeal+cancer/26545684.html Tue, 26 May 2026 07:00:54 -0400 A.06822034 A.08498496 A.20922990 A.50216777 CRBP O.00048977 O.01199884 O.20026344 O.22488230 O.54516537 http://www.streetinsider.com/FDA/Corbus+reports+CRB-701+shows+42.9%25+response+rate+in+oropharyngeal+cancer/26545684.html <p>Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) reported updated Phase 1/2 clinical trial data for its antibody drug conjugate CRB-701, showing a confirmed objective response rate of 42.9% in second-line oropharyngeal squamous cell carcinoma at the 3.6 mg/kg dose.</p> <p>The data, based on an April 1, 2026 data cut from a multi-center study conducted in the U.S. and Europe, included 317 patients across all tumor types and doses. In oropharyngeal cancer patients treated at 3.6 mg/kg, the median duration of response was 6.3 months and progression-free survival was 5.6 months.</p> <p>For cervical cancer patients at the same dose, CRB-701 demonstrated a confirmed objective http://www.streetinsider.com/FDA/Corbus+reports+CRB-701+shows+42.9%25+response+rate+in+oropharyngeal+cancer/26545684.html Tue, 26 May 2026 07:00:54 -0400 A.06822034 A.08498496 A.20922990 A.50216777 CRBP O.00048977 O.01199884 O.20026344 O.22488230 O.54516537 http://www.streetinsider.com/FDA/Corbus+reports+CRB-701+shows+42.9%25+response+rate+in+oropharyngeal+cancer/26545684.html <p>Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) reported updated Phase 1/2 clinical trial data for its antibody drug conjugate CRB-701, showing a confirmed objective response rate of 42.9% in second-line oropharyngeal squamous cell carcinoma at the 3.6 mg/kg dose.</p> <p>The data, based on an April 1, 2026 data cut from a multi-center study conducted in the U.S. and Europe, included 317 patients across all tumor types and doses. In oropharyngeal cancer patients treated at 3.6 mg/kg, the median duration of response was 6.3 months and progression-free survival was 5.6 months.</p> <p>For cervical cancer patients at the same dose, CRB-701 demonstrated a confirmed objective http://www.streetinsider.com/FDA/Corbus+reports+CRB-701+shows+42.9%25+response+rate+in+oropharyngeal+cancer/26545684.html Tue, 26 May 2026 07:00:54 -0400 A.06822034 A.08498496 A.20922990 A.50216777 CRBP O.00048977 O.01199884 O.20026344 O.22488230 O.54516537 http://www.streetinsider.com/FDA/Corbus+reports+CRB-701+shows+42.9%25+response+rate+in+oropharyngeal+cancer/26545684.html <p>Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) reported updated Phase 1/2 clinical trial data for its antibody drug conjugate CRB-701, showing a confirmed objective response rate of 42.9% in second-line oropharyngeal squamous cell carcinoma at the 3.6 mg/kg dose.</p> <p>The data, based on an April 1, 2026 data cut from a multi-center study conducted in the U.S. and Europe, included 317 patients across all tumor types and doses. In oropharyngeal cancer patients treated at 3.6 mg/kg, the median duration of response was 6.3 months and progression-free survival was 5.6 months.</p> <p>For cervical cancer patients at the same dose, CRB-701 demonstrated a confirmed objective http://www.streetinsider.com/FDA/Corbus+reports+CRB-701+shows+42.9%25+response+rate+in+oropharyngeal+cancer/26545684.html Tue, 26 May 2026 07:00:54 -0400 A.06822034 A.08498496 A.20922990 A.50216777 CRBP O.00048977 O.01199884 O.20026344 O.22488230 O.54516537 http://www.streetinsider.com/FDA/Corbus+reports+CRB-701+shows+42.9%25+response+rate+in+oropharyngeal+cancer/26545684.html <p>Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) reported updated Phase 1/2 clinical trial data for its antibody drug conjugate CRB-701, showing a confirmed objective response rate of 42.9% in second-line oropharyngeal squamous cell carcinoma at the 3.6 mg/kg dose.</p> <p>The data, based on an April 1, 2026 data cut from a multi-center study conducted in the U.S. and Europe, included 317 patients across all tumor types and doses. In oropharyngeal cancer patients treated at 3.6 mg/kg, the median duration of response was 6.3 months and progression-free survival was 5.6 months.</p> <p>For cervical cancer patients at the same dose, CRB-701 demonstrated a confirmed objective http://www.streetinsider.com/FDA/Corbus+reports+CRB-701+shows+42.9%25+response+rate+in+oropharyngeal+cancer/26545684.html Tue, 26 May 2026 07:00:54 -0400 A.06822034 A.08498496 A.20922990 A.50216777 CRBP O.00048977 O.01199884 O.20026344 O.22488230 O.54516537 http://www.streetinsider.com/FDA/Corbus+reports+CRB-701+shows+42.9%25+response+rate+in+oropharyngeal+cancer/26545684.html <p>Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) reported updated Phase 1/2 clinical trial data for its antibody drug conjugate CRB-701, showing a confirmed objective response rate of 42.9% in second-line oropharyngeal squamous cell carcinoma at the 3.6 mg/kg dose.</p> <p>The data, based on an April 1, 2026 data cut from a multi-center study conducted in the U.S. and Europe, included 317 patients across all tumor types and doses. In oropharyngeal cancer patients treated at 3.6 mg/kg, the median duration of response was 6.3 months and progression-free survival was 5.6 months.</p> <p>For cervical cancer patients at the same dose, CRB-701 demonstrated a confirmed objective http://www.streetinsider.com/FDA/Corbus+reports+CRB-701+shows+42.9%25+response+rate+in+oropharyngeal+cancer/26545684.html Tue, 26 May 2026 07:00:54 -0400 A.06822034 A.08498496 A.20922990 A.50216777 CRBP O.00048977 O.01199884 O.20026344 O.22488230 O.54516537